Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer

Journal:

Science Advances

Published:

2025-10-10

DOI:

10.1126/sciadv.adw7989

Affiliations:

7

Authors:

12

Go to article

Institutions	Authors	Share
State Key Laboratory of Molecular Oncology, China	5.000000	0.42
First Affiliated Hospital of Xinjiang Medical University, China	3.000000	0.25
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.08
Johns Hopkins University (JHU), United States of America (USA)	1.000000	0.08
Mayo Clinic, United States of America (USA)	1.000000	0.08
Beijing Hospital, China	1.000000	0.08

Interested in Medical Biochemistry and Metabolomics?